CN107405339A - 有机化合物 - Google Patents

有机化合物 Download PDF

Info

Publication number
CN107405339A
CN107405339A CN201680014968.7A CN201680014968A CN107405339A CN 107405339 A CN107405339 A CN 107405339A CN 201680014968 A CN201680014968 A CN 201680014968A CN 107405339 A CN107405339 A CN 107405339A
Authority
CN
China
Prior art keywords
disorder
disease
net
sert
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680014968.7A
Other languages
English (en)
Chinese (zh)
Inventor
李鹏
J·赵
L·P·文诺格勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CN107405339A publication Critical patent/CN107405339A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201680014968.7A 2015-03-20 2016-03-18 有机化合物 Pending CN107405339A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135915P 2015-03-20 2015-03-20
US62/135,915 2015-03-20
PCT/US2016/023198 WO2016154027A1 (en) 2015-03-20 2016-03-18 Organic compounds

Publications (1)

Publication Number Publication Date
CN107405339A true CN107405339A (zh) 2017-11-28

Family

ID=56977765

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680014968.7A Pending CN107405339A (zh) 2015-03-20 2016-03-18 有机化合物

Country Status (13)

Country Link
US (1) US10188758B2 (https=)
EP (1) EP3270920B1 (https=)
JP (1) JP6726200B2 (https=)
KR (1) KR20170129906A (https=)
CN (1) CN107405339A (https=)
AU (1) AU2016235483A1 (https=)
BR (1) BR112017020135A2 (https=)
CA (1) CA2978668A1 (https=)
ES (1) ES2819833T3 (https=)
IL (1) IL254320A0 (https=)
MX (1) MX2017012022A (https=)
RU (1) RU2017134796A (https=)
WO (1) WO2016154027A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113195489A (zh) * 2018-11-02 2021-07-30 埃斯特韦制药股份公司 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基吡啶衍生物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3339304A1 (en) 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Quinoline and isoquinoline derivatives for treating pain and pain related conditions
EP3339307A1 (en) * 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions
JP2022506378A (ja) * 2018-11-02 2022-01-17 エステベ ファーマシューティカルズ，ソシエダッド アノニマ 疼痛及び疼痛に関連する状態を処置するための新規なテトラヒドロピリミドジアゼピン及びテトラヒドロピリドジアゼピン化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ313076A (en) * 1995-07-24 1999-11-29 Lilly Co Eli Medicament containing duloxetine for treating hyperactivity and attention deficiency disorders
EP1587781A1 (en) * 2002-11-05 2005-10-26 Eli Lilly And Company 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
WO2007010082A1 (en) * 2005-07-15 2007-01-25 Fermion Oy Process for preparing a 3-aryloxy-3-arylpropylamine
EP2066630A1 (en) * 2006-08-23 2009-06-10 Pfizer Products Incorporated Piperidine derivatives
ES2553891T3 (es) * 2007-06-04 2015-12-14 Intra-Cellular Therapies, Inc. Derivados de piridina como moduladores NET/SERT
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
US9352218B2 (en) 2009-04-21 2016-05-31 Nintendo Co., Ltd. Game apparatus and computer-readable storage medium

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113195489A (zh) * 2018-11-02 2021-07-30 埃斯特韦制药股份公司 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基吡啶衍生物

Also Published As

Publication number Publication date
CA2978668A1 (en) 2016-09-29
ES2819833T3 (es) 2021-04-19
US10188758B2 (en) 2019-01-29
BR112017020135A2 (pt) 2018-05-29
EP3270920B1 (en) 2020-06-17
RU2017134796A (ru) 2019-04-04
EP3270920A4 (en) 2018-10-24
JP2018508556A (ja) 2018-03-29
MX2017012022A (es) 2018-01-30
WO2016154027A1 (en) 2016-09-29
JP6726200B2 (ja) 2020-07-22
AU2016235483A1 (en) 2017-10-12
IL254320A0 (en) 2017-11-30
EP3270920A1 (en) 2018-01-24
KR20170129906A (ko) 2017-11-27
US20180099060A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
JP6964450B2 (ja) 造影剤の合成および使用のための組成物、方法およびシステム
JP4477097B2 (ja) 中枢神経系障害の治療のための（２ｓ）−（４ｅ）−ｎ−メチル−５−［３−（５−イソプロポキシピリジン）イル］−４−ペンテン−２−アミンの多形形態
PT711289E (pt) Compostos piperazina utilizados em terapia
JP2001524954A (ja) コカインの類似化合物
CN110248655A (zh) 精神药剂及其用途
CA3232914A1 (en) Lsd derivatives, synthesis & method for treatment of diseases and disorders
JP6751161B2 (ja) フッ素含有トリアゾロピリジン系化合物、その製造方法、医薬組成物及び用途
JP6726200B2 (ja) 有機化合物
CN104725363B (zh) 取代的哌嗪化合物及其使用方法和用途
EP3860996A1 (en) Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
JP5384487B2 (ja) 新規方法
US10081600B2 (en) 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof
US20130338116A1 (en) Compounds and methods for the treatment of pain and other diseases
JP2010529080A (ja) 皮質カテコールアミン作動性神経伝達の調節因子としての新規な二置換フェニルピロリジン
KR20200097694A (ko) 통증 및 통증 관련 상태를 치료하기 위한 신규한 알콕시아미노 유도체
CN107459510B (zh) 异恶唑类化合物及其应用
JP2008528677A (ja) Ｃｎｓの疾患および障害の処置のための四環系モノアミン再取り込み阻害薬
JP2024524629A (ja) セロトニン５－ｈｔ２ａ、５－ｈｔ２ｂ、５－ｈｔ２ｃ受容体逆作動薬
CN118284607A (zh) 用于治疗疾病和障碍的lsd衍生物、合成和方法
AU2021329920A1 (en) Serotonin receptor modulators
Goyal Synthesis And Characterization Of Novel Valerophenone Oximes And Ethers Applicable In Psychiatric Disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171128